Abstract
Schizophrenia and diabetes have been known to be linked disorders for decades. One reason is due to the fact that a major side effect of antipsychotic medication treatment is metabolic syndrome, which increases the risk of the patients developing type 2 diabetes and cardiovascular disorders. However, signs of metabolic syndrome in schizophrenia patients were identified more than 100 years ago, even before the development of antipsychotic drugs. This suggests that schizophrenia itself predisposes towards diabetes and, in turn, insulin resistance may be a risk factor for the development of schizophrenia. This review summarizes the findings surrounding this issue and places them into context with regards to increasing our understanding of the aetiology of schizophrenia and in support of biomarker and drug discovery efforts.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1211–1259
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5), 5th edn. American Psychiatric Publishing, Washington, DC. ISBN-10: 8123923791
Zwicker A, Denovan-Wright EM, Uher R (2018) Gene-environment interplay in the etiology of psychosis. Psychol Med 48(12):1925–1936
Ventriglio A, Gentile A, Stella E, Bellomo A (2015) Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 9:297. https://doi.org/10.3389/fnins.2015.00297
Stoner SC (2018) Management of serious cardiac adverse effects of antipsychotic medications. Ment Health Clin 7(6):246–254
Hjorthøj C, Stürup AE, McGrath JJ (2017) Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4:295–301
Andrade C (2016) Cardiometabolic risks in schizophrenia and directions for intervention, 1: magnitude and moderators of the problem. J Clin Psychiatry 77(7):e844–e847. https://doi.org/10.4088/JCP.16f10997
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M et al (2018) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 13:757–777
Harris LW, Guest PC, Wayland MT, Umrania Y, Krishnamurthy D, Rahmoune H et al (2012) Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology 38(6):752–766
Chadda RK, Ramshankar P, Deb KS, Sood M (2013) Metabolic syndrome in schizophrenia: differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother 4(3):176–186
Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiat 74(3):261–269
Kohen D (2004) Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 47:S64–S66
Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160(2):284–289
Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481–445
Steiner J, Walter M, Guest P, Myint AM, Schiltz K, Panteli B et al (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15(1):3–4
Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15:118–119
Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M et al (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36:1092–1096
Serretti A, De Ronchi D, Lorenzi C, Berardi D (2004) New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 11(3):343–358
Haupt DW, Newcomer JW (2001) Hyperglycemia and antipsychotic medications. J Clin Psychiatry 62(Suppl 27):15–26
Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull 39(2):306–318
American Psychiatric Association (1997) American Psychiatric Association practice guideline for the treatment of patients with schizophrenia (American Psychiatric Association practice guidelines). American Psychiatric Press Inc, Washington, DC. ISBN-10: 0890423091
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA et al (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610
Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F et al (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166(2):152–163
Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S (2016) Metformin for clozapine associated obesity: a systematic review and Meta-analysis. PLoS One 11(6):e0156208. https://doi.org/10.1371/journal.pone.0156208
Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP et al (2005) Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 66:1116–1121
Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M et al (2018) Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. pii: S0163-7258(18)30114-1. https://doi.org/10.1016/j.pharmthera.2018.06.012. [Epub ahead of print]
Deng C, Weston-Green K, Huang XF (2010) The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuro-Psychopharmacol Biol Psychiatry 34(1):1–4
Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519–526
Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20:368–378
Chen J, Huang XF, Shao R, Chen C, Deng C (2017) Molecular mechanisms of antipsychotic drug-induced diabetes. Front Neurosci 11:643. https://doi.org/10.3389/fnins.2017.00643
Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z (2018) Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog Neuro-Psychopharmacol Biol Psychiatry 83:55–63
Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65(10):1335–1342
Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17(2):97–107
Saddichha S, Ameen S, Akhtar S (2008) Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 28(1):27–31
Taylor JH, Jakubovski E, Gabriel D, Bloch MH (2018) Predictors and moderators of antipsychotic-related weight gain in the treatment of early-onset schizophrenia spectrum disorders study. J Child Adolesc Psychopharmacol 28(7):474–484
Musil R, Obermeier M, Russ P, Hamerle M (2015) Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 14(1):73–96
Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60(6):358–363
Schwarz E, Steiner J, Guest PC, Bogerts B, Bahn S (2015) Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World J Biol Psychiatry 16(1):22–30
Meyer JM (2010) Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci 4:23–42
Guina J, Gupta A, Langleben DD, Elman I (2016) Clinical correlates of oral glucose tolerance test performance in olanzapine-treated patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 77(12):e1650–e1651
Tsuneyama N, Suzuki Y, Sawamura K, Sugai T, Fukui N, Watanabe J et al (2016) Effect of serum leptin on weight gain induced by olanzapine in female patients with schizophrenia. PLoS One 11(3):e0149518. https://doi.org/10.1371/journal.pone.0149518
Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatr 51:382–386
Timonen MJ, Saari KM, Jokelainen JJ, Meyer-Rochow VB, Räsänen PK, Koponen HJ (2009) Insulin resistance and schizophrenia: results from the Northern Finland 1966 Birth Cohort. Schizophr Res 113(1):107–108
van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L et al (2008) Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93:572–577
Uher R (2014) Gene-environment interactions in severe mental illness. Front Psych 5:48. https://doi.org/10.3389/fpsyt.2014.00048
Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S et al (2016) A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev 65:185–194
van de Leemput J, Hess JL, Glatt SJ, Tsuang MT (2016) Genetics of schizophrenia: historical insights and prevailing evidence. Adv Genet 96:99–141
Misiak B, Stramecki F, Gawęda Ł, Prochwicz K, Sąsiadek MM, Moustafa AA et al (2018) Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. Mol Neurobiol 55(6):5075–5100
Sengupta S, Parrilla-Escobar MA, Klink R, Fathalli F, Ng YK, Stip E et al (2008) Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res 102(1–3):329–336
Verma SK, Subramaniam M, Liew A, Poon LY (2009) Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 70(7):997–1000
Zhai D, Lang Y, Feng Y, Liu Y, Dong G, Wang X et al (2017) Early onset of cardiometabolic risk factor profiles in drug naïve adolescents and young adults with first-episode schizophrenia. Schizophr Res 190:60–62
Hutton JC (1994) Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases. Diabetologia 37(Suppl 2):S48–S56
Steiner J, Berger M, Guest PC, Dobrowolny H, Westphal S, Schiltz K et al (2017) Assessment of insulin resistance among drug-naive patients with first-episode schizophrenia in the context of hormonal stress axis activation. JAMA Psychiat 74(9):968–970
Petruzzelli MG, Margari M, Peschechera A, de Giambattista C, De Giacomo A, Matera E et al (2018) Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis. BMC Psychiatry 18(1):246. https://doi.org/10.1186/s12888-018-1827-3
Walker E (2002) Risk factors, and the neurodevelopmental course of schizophrenia. Eur Psychiatry 17(Suppl 4):363s–369s
Trotman HD, Holtzman CW, Ryan AT, Shapiro DI, MacDonald AN, Goulding SM et al (2013) The development of psychotic disorders in adolescence: a potential role for hormones. Horm Behav 64(2):411–419
Soria V, González-Rodríguez A, Huerta-Ramos E, Usall J, Cobo J, Bioque M et al (2018) Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis. Psychoneuroendocrinology 93:8–19
Qiu H, Yang JK, Chen C (2017) Influence of insulin on growth hormone secretion, level and growth hormone signalling. Sheng Li Xue Bao 69(5):541–556
Melmed S (1984) Insulin suppresses growth hormone secretion by rat pituitary cells. J Clin Invest 73(5):1425–1433
Krishnamurthy D, Harris LW, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S et al (2013) Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry 14(7):478–489
Iglesias P, Bernal C, Díez JJ (2014) Curious cases: acromegaly and schizophrenia: an incidental association? Schizophr Bull 40(4):740–743
Hofmann G (1953) Demonstration of a case of schizophrenia in acromegaly. Wien Z Nervenheilkd Grenzgeb 7:244–251
Schiffter R (1971) Problems of schizophrenic-like psychoses in pituitary disorders. Psychiatr Clin (Basel) 4:82–99
Schulte DB (1976) Paranoid-hallucinatory psychoses in acromegaly. Schweiz Arch Neurol Neurochir Psychiatr 118:357–377
Pinto D, Safeekh AT, Trivedi M (2005) Psychotic symptoms in acromegaly. Indian J Psychiatry 47:58–59
Kannabiran M, Singh V, Grewal S (2006) Acromegaly presenting as psychotic disorder in a patient with familial autosomal dominant polycystic kidney disease. Ger J Psychiatry 9:136–138
Koroglu A, Hocaoglu C (2012) Risperidone-induced acromegaly: a case report. Ther Adv Psychopharmacol 2:85–89
Künzel H, Held K, Schmidt D, Ziegenbein M, Murck H, Steiger A (2018) Sleep-endocrine effects of growth hormone-releasing hormone (GHRH) in patients with schizophrenia. J Psychiatr Res 101:1–4
Joseph JJ, Golden SH (2017) Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci 1391(1):20–34
Nordholm D, Rostrup E, Mondelli V, Randers L, Nielsen MØ, Wulff S et al (2018) Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients. Psychoneuroendocrinology 92:72–80
Azcoitia I, Doncarlos LL, Garcia-Segura LM (2002) Estrogen and brain vulnerability. Neurotox Res 4(3):235–245
Seeman MV, Lang M (1990) The role of estrogens in schizophrenia gender differences. Schizophr Bull 16(2):185–194
Lindamer LA, Lohr JB, Harris MJ, Jeste DV (1997) Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33(2):221–228
Kulkarni J (2005) Oestrogen--a new treatment approach for schizophrenia? Med J Aust 190(4 Suppl):S37–S38
Huber TJ, Tettenborn C, Leifke E, Emrich HM (2005) Sex hormones in psychotic men. Psychoneuroendocrinology 30(1):111–114
Ramsey JM, Schwarz E, Guest PC, van Beveren NJ, Leweke FM, Rothermundt M et al (2013) Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One 8(11):e78729. https://doi.org/10.1371/journal.pone.0078729
Walker JJ, Terry JR, Lightman SL (2010) Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. Proc Biol Sci 277(1688):1627–1633
Daimon M, Kamba A, Murakami H, Mizushiri S, Osonoi S, Yamaichi M et al (2017) Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS One 12(4):e0175204. https://doi.org/10.1371/journal.pone.0175204
Tannenbaum GS, Martin JB, Colle E (1976) Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. Endocrinology 99:720–727
Akamine EH, Marçal AC, Camporez JP, Hoshida MS, Caperuto LC, Bevilacqua E et al (2010) Obesity induced by high-fat diet promotes insulin resistance in the ovary. J Endocrinol 206(1):65–74
Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863–2886
Garcia GE, Gabbai FB, O’Connor DT, Dinh TQ, Kennedy B, Ziegler MG et al (1994) Does chromostatin influence catecholamine release or blood pressure in vivo? Peptides 15:195–197
Tatemoto K, Efendić S, Mutt V, Makk G, Feistner GJ, Barchas JD (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324(6096):476–478
Efendić S, Tatemoto K, Mutt V, Quan C, Chang D, Ostenson CG (1987) Pancreastatin and islet hormone release. Proc Natl Acad Sci U S A 84(20):7257–7260
Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M et al (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124:1325–1336
Kurzthaler I, Fleischhacker WW (2001) The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62(Suppl 7):32–37
Warren KR, Ball MP, Feldman S, Liu F, McMahon RP, Kelly DL (2011) Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia. Biol Res Nurs 13(4):383–390
Kimhy D, Khan S, Ayanrouh L, Chang RW, Hansen MC, Lister A et al (2016) Use of active-play video games to enhance aerobic fitness in schizophrenia: feasibility, safety, and adherence. Psychiatr Serv 67(2):240–243
Yoon S, Ryu JK, Kim CH, Chang JG, Lee HB, Kim DH et al (2016) Preliminary effectiveness and sustainability of group aerobic exercise program in patients with schizophrenia. J Nerv Ment Dis 204(9):644–650
Zheng W, Li X-B, Tang Y-L, Xiang Y-Q, Wang C-Y, de Leon J (2015) Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 35:499–509
Stroup TS, Gray N (2018) Management of common adverse effects of antipsychotic medications. World Psychiatry 17(3):341–356
Hendrick V, Dasher R, Gitlin M, Parsi M (2017) Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin. Ann Clin Psychiatry 29(2):120–124
Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25–33
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
Salpeter SR, Buckley NS, Kahn JA, Salpeter EE (2008) Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 121:149–157
Siskind D, Friend N, Russell A, McGrath JJ, Lim C, Patterson S et al (2018) CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ Open 8(3):e021000. https://doi.org/10.1136/bmjopen-2017-021000
Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G et al (2005) Is dehydroepiandrosterone a hormone? J Endocrinol 187(2):169–196
Mo Q, Lu SF, Simon NG (2006) Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol 99(1):50–58
Seeman E (2001) Raloxifene. J Bone Miner Metab 19(2):65–75
Henderson E, Weinberg M, Wright WA (1950) Pregnenolone. J Clin Endocrinol Metab 10(4):455–474
Guest PC, Chan MK, Gottschalk MG, Bahn S (2014) The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients. Biomark Med 8(1):15–27
Joyce DW, Kehagia AA, Tracy DK, Proctor J, Shergill SS (2017) Realising stratified psychiatry using multidimensional signatures and trajectories. J Transl Med 15(1):15. https://doi.org/10.1186/s12967-016-1116-1
Guest FL, Guest PC (2018) Point-of-care testing and personalized medicine for metabolic disorders. Methods Mol Biol 1735:105–114
Pratt J, Hall J (2018) Biomarkers in neuropsychiatry: a Prospect for the twenty-first century? Curr Top Behav Neurosci. https://doi.org/10.1007/7854_2018_58. [Epub ahead of print]
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Guest, P.C. (2019). Insulin Resistance in Schizophrenia. In: Guest, P. (eds) Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders. Advances in Experimental Medicine and Biology(), vol 1134. Springer, Cham. https://doi.org/10.1007/978-3-030-12668-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-12668-1_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-12667-4
Online ISBN: 978-3-030-12668-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)